NL-OMON32481尚未招募2 期
Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) An open label multicenter randomized phase II study. A study of the Dutch Head and Neck Cancer Group (DHNCG) (NWHHT 08-02) - TyvTax
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 74 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •>=18 years of age
- •Histologically or cytologically confirmed diagnosis of SCCHN
- •Local or locoregional recurrence not amendable for local therapy or metastatic disease
- •Tumor tissue available for immunohistochemical evaluation of EGFR 1 and 2 expression
- •Measurable or evaluable disease (RECIST)
- •WHO performance 0-2
- •Effective contraception for both male and female subjects if risk of conception exists
- •Neutrophils >=1.5 x 109 cells/L, platelet count >= 100 x 109 cells/L and hemoglobin >= 6 mmol/L
- •Total bilirubin within normal institutional limits (ULN)
- •Aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) <=2.5 × ULN
- •Creatinin within normal institutional limits or Creatinine clearance > 60 mL/min
- •Cardiac ejection fraction >= 50% as measured by echocardiogram or MUGA scan
- •Signed written informed consent before any study related activities are carried out
- •Expected adequacy of follow-up
排除标准
- •Patients previously treated with EGFR inhibitor
- •Patients previously treated with Docetaxel or Paclitaxel
- •Nasopharyngeal carcinoma
- •Active infection (infection requiring IV antibiotics), including active tuberculosis, and known and declared HIV.
- •Pregnancy (absence confirmed by serum or urine β-HCG test) or lactation period
- •Concurrent treatment with any other anti-cancer therapy.
- •Class 3-4 cardiac morbidity, as defined by the new York Heart association Criteria (e.g. uncontrolled or symptomatic congestive heart failure, myocardial infarction within six months prior to the start of study, uncontrolled or symptomatic angina) and any cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
- •Current active hepatic or biliary disease (with exception of Gilbert*s syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •Renal function as measured by creatinine clearance <30 ml/min
- •Presence of severe and/or uncontrolled concurrent medical disease (e.g. uncontrolled diabetes mellitus, uncontrolled liver disease, including chronic viral hepatitis judged at risk of reactivation, uncontrolled active infection such as HIV infection, etc.)
- •Concomitant (or within 4 weeks before randomisation) administration of any other experimental drug under investigation; Chemotherapy or other anti-cancer therapy for the recurrence or metastatic disease; chemotherapy for initial treatment, i.e. chemoradiotherapy, is allowed, unless it has been stopped 3 weeks before inclusion
研究者
相似试验
招募中
不适用
Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). An open label multicenter randomized phase II study.A study of the Dutch Head and Neck Cancer Group (DHNCG)(NWHHT 08-02).patients with recurrent SCCHN not amendable for local therapy or patients with metastatic SCCHNKeywords: SCCHN, recurrent and/or metastatic disease, docetaxel, lapatinibNL-OMON22962The Netherlands Cancer Institute Antoni van Leeuwenhoek hospitalDutch Head and Neck Cancer Group (DHNCG)74
招募中
3 期
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)10038597prostate cancerNL-OMON54758Memorial Sloan Kettering Cancer Center250
进行中（未招募）
1 期
Trial comparing subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with Docetaxel vs. subjects treated with a combination of Docetaxel and Radium-223Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC)EUCTR2018-002944-10-NLMemorial Sloan Kettering Cancer Center738
进行中（未招募）
1 期
A Phase I-II Study of Lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancerocally advanced/inflammatory or large operable breast cancerMedDRA version: 8.1 Level: LLT Classification code 10021974 Term: Inflammatory breast cancerEUCTR2006-000864-94-FREuropean Organisation for Research and Treatment of Cancer128
进行中（未招募）
不适用
A phase I-II study of lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer. - Lapataxocally advanced/inflammatory or large operable brest cancer.MedDRA version: 16.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-000864-94-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)180